CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $54.74, moving -2.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with ...

For those willing to take a chance, let's consider two biotech stocks that could eventually become solid, well-established drugmakers: CRISPR Therapeutics ( CRSP 0.76%) and Viking Therapeutics ( VKTX ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three ...

Detailed price information for Ark Genomic Revolution ETF (ARKG-A) from The Globe and Mail including charting and trades.

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...